These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

545 related items for PubMed ID: 19318950

  • 1. The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer.
    Reed AB, Parekh DJ.
    Curr Opin Urol; 2009 May; 19(3):238-42. PubMed ID: 19318950
    [Abstract] [Full Text] [Related]

  • 2. High-grade prostate cancer and finasteride.
    Lebdai S, Bigot P, Azzouzi AR.
    BJU Int; 2010 Feb; 105(4):456-9. PubMed ID: 19930174
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge.
    Andriole G, Bostwick D, Civantos F, Epstein J, Lucia MS, McConnell J, Roehrborn CG.
    J Urol; 2005 Dec; 174(6):2098-104. PubMed ID: 16280736
    [Abstract] [Full Text] [Related]

  • 7. Prostate cancer prevention and finasteride.
    D'Amico AV, Barry MJ.
    J Urol; 2006 Nov; 176(5):2010-2; discussion 2012-3. PubMed ID: 17070238
    [Abstract] [Full Text] [Related]

  • 8. Looking back at PCPT: looking forward to new paradigms in prostate cancer screening and prevention.
    Canby-Hagino E, Hernandez J, Brand TC, Thompson I.
    Eur Urol; 2007 Jan; 51(1):27-33. PubMed ID: 17030406
    [Abstract] [Full Text] [Related]

  • 9. Pharmacological approaches to reducing the risk of prostate cancer.
    Rittmaster RS, Fleshner NE, Thompson IM.
    Eur Urol; 2009 May; 55(5):1064-73. PubMed ID: 19200641
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
    Musquera M, Fleshner NE, Finelli A, Zlotta AR.
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1073-9. PubMed ID: 18588452
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.
    Etzioni RD, Howlader N, Shaw PA, Ankerst DP, Penson DF, Goodman PJ, Thompson IM.
    J Urol; 2005 Sep; 174(3):877-81. PubMed ID: 16093979
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.